LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
48.60
+1.66 (3.54%)
At close: Oct 8, 2025, 4:00 PM EDT
47.65
-0.95 (-1.95%)
After-hours: Oct 8, 2025, 6:26 PM EDT
LENZ Therapeutics Revenue
LENZ Therapeutics had revenue of $5.00M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $5.00M.
Revenue (ttm)
$5.00M
Revenue Growth
n/a
P/S Ratio
268.29
Revenue / Employee
$454,545
Employees
11
Market Cap
1.39B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 15.00M | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLENZ News
- 8 days ago - LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States - PRNewsWire
- 8 days ago - LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States - GlobeNewsWire
- 4 weeks ago - LENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - LENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 6 weeks ago - LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences - GlobeNewsWire
- 2 months ago - LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia - GlobeNewsWire
- 2 months ago - LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 2 months ago - LENZ Therapeutics: Undervalued Ahead Of PDUFA - Seeking Alpha